Results from a Phase III Trial Analyzing Obinutuzumab (GA101) in CLL
Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.